The promotion of new drugs could be more effective
Some of the resources invested by the pharmaceutical industry in promoting new drugs could be spent more effectively. ‘Drugs manufacturers cannot do without promotional activities, but at the same time there’s a lot of ignorance about the compilation of the ideal mix of promotional activities in the pharmaceutical market’, says Sara Kremer. She will be awarded a PhD by the University of Groningen on 11 February.
Kremer researched how pharmaceutical manufacturers could do a better job of drawing the attention of doctors to their products. It’s a tricky subject, the PhD student acknowledges. ‘The pharmaceutical market is one where major profits are made and huge sums are involved in promoting health. A great number of promotional activities are used to increase profits in this market. The strongly commercial aspect of a market that revolves around health is a sensitive combination.’
Not easy
However, pharmaceutical companies cannot do without promotional activities, explains Kremer. ‘Pharmaceutical manufacturers have to earn back their huge investments in a limited number of years, before the patent runs out. That is only possible by actively drawing the attention of doctors to the new product.’ When promoting their drugs in the Netherlands, manufacturers are only allowed to concentrate on doctors and medical specialists. And it’s not easy to influence those professionals, says Kremer. ‘Doctors are only slightly susceptible to promotional activities. When prescribing medication, doctors often choose from a fixed set of drugs. Manufacturers have their work cut out to ensure that their drugs are included in that set.’
Drug salespersons
Kremer demonstrates that the use of drug salespersons is usually the most effective way of promoting drugs. ‘A drug salesperson is happy if he or she gets ten minutes to introduce a new product. Nevertheless, those few minutes of direct contact are crucial to gaining a foothold in the fixed set of products used by that doctor.’
Consumers
Kremer also investigated the pharmaceutical industry in the United States, where promotional activities directed towards consumers are permitted.The PhD student demonstrated that in general, these are less effective than activities directed towards doctors. On the other hand, Kremer did find a positive effect when both instruments are used simultaneously. ‘I could imagine that it would be beneficial to permit promotional activities directed towards consumers in the Netherlands as well’, says Kremer. ‘Health is becoming more and more important to many people and patients are becoming more articulate. Patients with chronic diseases in particular are very involved in their treatment plans. By providing that group with more information about the range of drugs, they could gain more influence over what is prescribed.’
Effect on welfare
In that way activities directed towards promoting new drugs could have a positive effect on general welfare, claims Kremer. ‘It is important that an innovative drug, for example that has fewer side effects or is easier to use, becomes known about and is prescribed by doctors. In addition, promotional activities could also ensure that a new drug reaches potential users faster. That would have a positive effect on the general welfare of a population.’
Curriculum vitae
Sara Kremer (Vries, 1981) will be awarded her PhD on 11 February 2010 by the Faculty of Economics and Business of the University of Groningen. The title of her thesis is ‘Examining the effectiveness of promotional expenditures for pharmaceutical products’. Her supervisors were Prof. P.S.H. Leeflang and Dr J.E. Wieringa. Kremer conducted her research at the SOM research school of the University of Groningen. Kremer currently works for GfK Daphne Communication Management as a Senior Project Manager Research.
Contact
Sara Kremer, sara.kremer@gfk.com
Last modified: | 13 March 2020 01.58 a.m. |
More news
-
01 April 2025
UGBS Executive MBA best-rated MBA | Dutch Master's Guide 2025
According to the independent Keuzegids Masters 2025, the Executive MBA of the University of Groningen Business School is the best rated MBA in the Netherlands (both part-time and full-time programmes).
-
01 April 2025
Executive Master of M&A and Valuation accredited as joint degree with Vrije Universiteit Amsterdam
Starting 1 September, participants enrolled in the programme will receive a master's degree from both the University of Groningen and Vrije Universiteit Amsterdam upon successful completion.
-
24 March 2025
UG 28th in World's Most International Universities 2025 rankings
The University of Groningen has been ranked 28th in the World's Most International Universities 2025 by Times Higher Education. With this, the UG leaves behind institutions such as MIT and Harvard. The 28th place marks an increase of five places: in...